ANRO · Alto Neuroscience, Inc.
$24.01
-0.79 (-3.19%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.06B
Shares
39.24M
Volume · Oct 5
550.29K
Avg daily vol (3M)
551.83K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.01
Open$24.63
Day$23.80–25.85
52W close$5.62–36.64
Avg vol 30d576K
Short int4.2M · 10.6% float · 9.1d
Short vol87%
Last earningsMar 16, 2026
DataFeb 2024–Oct 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$84.24M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$227.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+58.1%
Year over year · more shares
Price change (1Y)
+462.4%
Trailing year
Short interest
10.6%
Latest settlement · 9.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
−22%
below
RSI (14)
23
oversold
MACD trend
Negative
52-week position
59%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−32%
trailing
6-month return
−7%
trailing
YTD return
+35%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $31 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
1 of 116 funds reported for Sep 30 · net +121 sh shares · +1 new
Insider flow
Distributing
Net -$3.6M over 90 days · 100% sells
Short interest
Rising
10.64% of float · ▲ +8.8% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
116 holders — near 2-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
EPS growth
+12%
Y/Y
Free cash flow
$-51.8M
Balance sheet
$159.7M
net cash
Quant / Vol
risk profile
Volatility
114%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
7.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
−22%
Bearish
RSI (14)
23
Neutral
MACD trend
Negative
Bearish
52-week position
59%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $31 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
1 of 116 funds reported for Sep 30 · net +121 sh shares · +1 new
Insider flow
Distributing
Net -$3.6M over 90 days · 100% sells
Short interest
Rising
10.64% of float · ▲ +8.8% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
116 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $24 · 59%
Range high $37
vs 200-day avg +1%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANRO
this stock
Alto Neuroscience, Inc.
|
$1.06B | +34.9% | — | — | 10.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANRO | -9.9% | -32.5% | -7.0% | -6.0% | +34.9% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -11.1% | -33.1% | -18.6% | -7.6% | +21.3% |